Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
106 hedge funds and large institutions have $485M invested in Marinus Pharmaceuticals, Inc in 2023 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 22 closing their positions.
457% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $1.99M
91% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 22
71% more capital invested
Capital invested by funds: $284M → $485M (+$201M)
23% more funds holding
Funds holding: 86 → 106 (+20)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.7M |
| 2 |
Jennison Associates
New York
|
+$16M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.97M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.7M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$9.22M |
| 3 |
Millennium Management
New York
|
-$7.86M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$6.83M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$6.63M |
MRNS Hedge Fund Activity: Q2 2023 in Review
106 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2023, worth a combined $485M — up 71% from $284M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new MRNS positions and 22 closed out — a net gain of 20 holders — while 23 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $23.7M. The largest seller was Point72 Asset Management, cutting an estimated $15.7M.
- 106 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2023, up from 86 in Q1 2023.
- Funds reported $485M of Marinus Pharmaceuticals, Inc stock for Q2 2023, up 71% quarter-over-quarter.
- 42 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2023 and 22 closed out, a net change of +20 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2023 was BlackRock, an estimated $23.7M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2023 was Point72 Asset Management, an estimated $15.7M sold.
Based on aggregated 13F filings for Q2 2023.